ATE406896T1 - Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten - Google Patents

Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Info

Publication number
ATE406896T1
ATE406896T1 AT03713475T AT03713475T ATE406896T1 AT E406896 T1 ATE406896 T1 AT E406896T1 AT 03713475 T AT03713475 T AT 03713475T AT 03713475 T AT03713475 T AT 03713475T AT E406896 T1 ATE406896 T1 AT E406896T1
Authority
AT
Austria
Prior art keywords
dopamine
monoester
asymmetrically substituted
receptor agonist
agonist prodrugs
Prior art date
Application number
AT03713475T
Other languages
English (en)
Inventor
Durk Dijkstra
Hakan Wikstrom
Original Assignee
Darpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200478A external-priority patent/SE0200478D0/xx
Priority claimed from SE0200474A external-priority patent/SE0200474D0/xx
Application filed by Darpharma Inc filed Critical Darpharma Inc
Application granted granted Critical
Publication of ATE406896T1 publication Critical patent/ATE406896T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03713475T 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten ATE406896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200478A SE0200478D0 (sv) 2002-02-15 2002-02-15 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929
SE0200474A SE0200474D0 (sv) 2002-02-17 2002-02-17 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline

Publications (1)

Publication Number Publication Date
ATE406896T1 true ATE406896T1 (de) 2008-09-15

Family

ID=27759833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03713475T ATE406896T1 (de) 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Country Status (11)

Country Link
US (1) US7220754B2 (de)
EP (1) EP1480647B1 (de)
JP (1) JP2005526728A (de)
AT (1) ATE406896T1 (de)
AU (1) AU2003217430B2 (de)
CA (1) CA2476115A1 (de)
DE (1) DE60323339D1 (de)
DK (1) DK1480647T3 (de)
ES (1) ES2314189T3 (de)
NO (1) NO20043634L (de)
WO (1) WO2003070245A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
WO2005062894A2 (en) * 2003-12-23 2005-07-14 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8596306B2 (en) * 2005-10-27 2013-12-03 Synthetic Gas Solutions, Llc Perfluorocarbon gas insufflation
WO2007098462A2 (en) * 2006-02-21 2007-08-30 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
WO2010124005A1 (en) 2009-04-21 2010-10-28 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
ES2649144T3 (es) * 2012-11-08 2018-01-10 Pfizer Inc. Compuestos heteroaromáticos y su uso como ligandos de dopamina D1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282227A (en) 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
US4340600A (en) 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L‐ドーパ誘導体
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
KR100292928B1 (ko) * 1992-05-26 2001-11-05 프란시스 제이 메이어 치환된헥사하이드로벤조페난트리딘
JP2710695B2 (ja) * 1993-04-06 1998-02-10 アボツト・ラボラトリーズ ドーパミンアゴニストとしての四環式化合物
JPH10502923A (ja) * 1994-07-15 1998-03-17 パーデュー・リサーチ・ファンデーション ジヒドレキシジンおよびその置換類似体の光学活性異性体
ES2169257T3 (es) 1995-08-18 2002-07-01 Purdue Research Foundation Nuevas isoquinolinas fusionadas como ligandos del receptor de la dopamina.

Also Published As

Publication number Publication date
WO2003070245B1 (en) 2004-05-27
EP1480647A4 (de) 2005-07-13
EP1480647B1 (de) 2008-09-03
AU2003217430B2 (en) 2008-10-23
NO20043634L (no) 2004-11-11
ES2314189T3 (es) 2009-03-16
EP1480647A1 (de) 2004-12-01
DE60323339D1 (de) 2008-10-16
CA2476115A1 (en) 2003-08-28
JP2005526728A (ja) 2005-09-08
WO2003070245A1 (en) 2003-08-28
US7220754B2 (en) 2007-05-22
US20050096469A1 (en) 2005-05-05
DK1480647T3 (da) 2009-01-26
AU2003217430A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
HRP20050191B1 (hr) Novi derivati benzoimidazola korisni kao antiproliferativna sredstva
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
NZ514409A (en) C7 ester substituted taxanes as antitumor agents
CR9587A (es) Derivados de piridazina
CY1112941T1 (el) Δικυκλικοι αναστολεις της μεκ
AR040870A1 (es) Compuestos inhibidores de proteinquinasas y composicion farmaceutica que los comprende
ECSP014097A (es) Derivados de tiofeno utiles como agentes anticancerosos
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
GT200100196A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
HK1097273A1 (en) Aminopyrones and their use as atm inhibitors
CA2589438C (en) Treatment of inflammatory bowel disease
MX2010007023A (es) Agonistas del receptor glucocorticoide sustituido de c20-c21.
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
CO5590918A2 (es) Formulaciones
DE60330356D1 (en) Stickstoff-lost-derivaten
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
ATE406896T1 (de) Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
MX9307608A (es) Inhibidores de la liberacion de la citocina y antagonistas de la il-1,procedimiento para su preparacion y composiciones farmaceuticas que loscontienen.
AR004512A1 (es) Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados
AR052488A1 (es) Derivados de 2-quinolonas como inhibidores de fosfodiesterasas
DE60002733D1 (de) Diester prodrugs von decahydroischinoline-3-carbonsäure
MY137868A (en) Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation and ummunologically-mediated diseases
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties